Emily Kimber is a journalist and editorial assistant, specializing in the field of pharmaceuticals and healthcare. With a focus on providing accurate and timely information to industry professionals, Emily's work has been featured in PMLiVE and PharmaTimes Media Ltd. Her articles cover a range of topics including drug approvals, clinical trial results, and regulatory updates.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Emily Kimber's articles mainly focus on healthcare and pharmaceutical industries, with an emphasis on press releases and data citations. To effectively reach out to her, consider offering newsworthy content related to drug trials, FDA approvals, advancements in biopharmaceuticals or cancer treatment. Furthermore, she may be interested in exclusive insights from industry experts regarding the latest developments within these areas.
Given Emily’s wide coverage of pharmaceutical companies and their activities, providing her with exclusive access to insider information about company developments or potential future trends could increase the chances of successful engagement.
As there is no specific geographic focus mentioned for Emily Kimber’s coverage area, it is advisable to tailor pitches that are globally relevant within the healthcare and pharmaceutical sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Emily Kimber
More than 26 million people in the US are affected by the inflammatory skin disease
Since the Orphan Drug Act was passed in 1983, pharmaceutical companies have increasingly focused on developing treatments for rare diseases. As a result, competition in the rare disease field is intensifying, with multiple therapies available for a growing number of these conditions. While not every rare disease has a treatment, the landscape is evolving, bringing new opportunities and challenges for clinicians and patients. This evolution requires a new way of thinking to educate clinicians and patients alike on these new treatments.
How to answer the most difficult questions in your strategy review
Navigating the present while positioning therapies for long-term success
Technology’s ability to accelerate the pace of innovation while reducing the cost is changing the dynamic of the struggle against cancer in myriad ways
By: Emily Kimber
The rare liver disease affects approximately 15 per 100,000 people in Europe
By: Emily Kimber
The site will be designed to accommodate multiple product types within rare diseases
Critical insights to prepare for market access success
More than 450,000 people are diagnosed with lung cancer each year in Europe
Caregivers often play an integral role during interactions with medical professionals
(833) 317-6278 
